Remyelination and ageing: Reversing the ravages of time
- PMID: 31687878
- PMCID: PMC7682531
- DOI: 10.1177/1352458519884006
Remyelination and ageing: Reversing the ravages of time
Abstract
Remyelination is a neuroprotective regenerative response to demyelination that restores saltatory conduction and decreases the vulnerability of axons to irreversible degeneration. It is a highly efficient process: however, as with all regenerative processes, its efficiency declines with ageing. Here we argue that this age-related decline in remyelination has a major impact on the natural history of multiple sclerosis (MS), a disease often of several decades' duration. We describe recent work on (1) how ageing changes the function of oligodendrocyte progenitor cells (OPCs), the cells primarily responsible for generating new myelin-forming oligodendrocytes in remyelination, (2) how these changes are induced by age-related changes in the OPC niche and (3) how these changes can be reversed, thereby opening up the possibility of therapeutically maintaining remyelination efficiency throughout the disease, preserving axonal health and treating the progressive phase of MS.
Keywords: Remyelination; ageing; oligodendrocyte progenitor cell; stem cell.
Conflict of interest statement
Figures

References
-
- Tintore M, Vidal-Jordana A, Sastre-Garriga J. Treatment of multiple sclerosis: Success from bench to bedside. Nat Rev Neurol 2019; 15(1): 53–58. - PubMed
-
- Faissner S, Plemel JR, Gold R, et al. Progressive multiple sclerosis: From pathophysiology to therapeutic strategies. Nat Rev Drug Discov 2019; 378(Pt 1): 169–180. - PubMed
-
- Ciotti JR, Cross AH. Disease-modifying treatment in progressive multiple sclerosis. Curr Treat Options Neurol 2018; 20(5): 12. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical